FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES
|
|
- Julia Bennett
- 5 years ago
- Views:
Transcription
1 FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES Cape Winelands Anova Conference 2013 Worcester Lindsay Wilson 3 June 2013
2 What is a fixed dose combination [FDC]? Pharmaceutical formulation that contains more than one active ingredient in specific proportions Many ARV and other FDC products available : AVOID using terminology SA just not accessed them until now Zidovudine / Lamivudine / Nevirapine Stavudine / Lamivudine / Efavirenz Tenofovir Emtricitabine Efavirenz Benefits: improve reliability / security of supplies: only ONE product to manage BUT converse applies: needs careful management ensures correct dosages reduce work loads: depot level to facility level reduce storage space: depot level to facility level reduce transport costs deduce: reduced pilferage reduced pill burden promotes adherence [evidence? likely but extent not quantifiable.. DON T rely on it patients still need support and counselling. Could argue easier to forget 1 tablet vrs 3?] 2
3 Who is eligible? National notice: signed 12 th Feb New patients [adults; adolescents and pregnant eligible to start ART] 2. All pregnant women needing triple therapy and breastfeeding mothers currently on a FDC compatible regimen 3. Virally suppressed patients currently on first line regimen requiring a switch due to toxicity [stavudine] 4. Patients currently stable on a TDF based regimen with TB comorbidity 5. Patients currently stable on a TDF based regimen with other comorbidities [e.g.hypertension ] 6. Patients currently stable on TDF based regimen and who request a switch to a FDC 7. Patients currently stable on TDF based regimen and who after counselling agree to a switch to FDC QUANTIFIABLE? 3
4 WC notice H [21 st March 2013] The use of this product will initially be limited ONLY for use in patients who are INITIATING antiretroviral therapy [ART] from the 1 st April 2013 [or as and when stock is received at a facility level]. deviation from this shall jeopardize patients who have been placed on this product. Sites are requested to ACTIVELY manage the monthly increased requirements of this product and subsequent reduction in use of the individual products by: Liaising with the ART clinic staff regarding numbers of new patients initiating treatment Accurately completing the ARV month end report and ordering accordingly, based on both usage and expected need. Kindly note: medicine wastage through expiry of individual product line items is not acceptable. Kindly note: any change of guidelines should only be implemented on receipt of a formal circular from the Western Cape Department of Health. 4
5 What they look like more coming! 5
6 Roll out time-frame: we don t know! 14 th May 2013 ARV depot stock on hand: ARV depot stock on order: Total: Adults RIC: New adults per month: Suggestion is to go with club patients through CDU first.. Comments? Need: Stock holding: minimum ARV depot: 2 months Site level: 1 to 2 months Aim: October 2013: New patients: Old patients: [ x 3] Total: % of the way there 6
7 Considerations Tender only awarded: 29 th November 2012 Christmas period: shut down Gear up period required: 3 to 6 months Production: raise capital: new machines / space / staff and implement Source large quantities of API [active pharmaceutical ingredient: all from same source!] Import: sea time [3 months] Regulatory requirements: MCC [all of above!] Quality assurance on all changes Strike season: June: affecting most of suppliers Gear up for Nov / Dec NDOH notice: 1 month x 3 and then 3 months at a time! SA: 16.5% of international need [5.6mil of 34 mil] 7
8 Monitoring: stock Facility month end report: unfortunately still required: amended 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Total number of patients [second line] Total number of patients [first line "average"] / month Province: 2 weekly stock situation reports to NDOH 2 and a half years! [TDF never over 3 weeks stock] 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% QUARTER 1 QUARTER QUARTER QUARTER Average FDC per month Average tenofovir usage per month 8
9 Monitoring: prescribing APP: top 10 ARV s vrs proportion of patients Province Cape W Q3 cum forecast Q3 cum usage % deviance % deviance Tenofovir 300mg tablets Efavirenz 600mg tablets Lamivudine 300mg tablets Lamivudine 150mg tablets Nevirapine 200mg tablets Stavudine 30mg capsules Lamivudine/Zidovudine 150/300mg tablets Lopinavir/Ritonavir 200/50mg tablets Lopinavir/Ritonavir 80/20mg/ml solution 60ml Abacavir 20mg/ml solution 240ml
10 Monitoring: Clinical Side Effects / Interactions / Efficacy: assume all the same as individual products: not tested renal impairment: will have to use individual products Interactions of ONE of the products have to use individual products and tailor doses or change medicine No reduced side effects and increased efficacy [as per NDOH advertising] Take on an empty stomach [contrary to NDOH notices take with food] - at night [reduce side effects of Efavirenz] 10
11 Per protocol, how clinical stationery must be completed Western Cape Government 2012
12 How to document FDC Indicate FDC FDC TDF 300mg/FTC 200mg /EFV 600mg FDC must be written on one line Please note: watch for differences between 3TC and FTC Western Cape Government 2012 Please do NOT write Odumine
13 How to capture in TIER.net and ekapa Western Cape Government 2012
14 Contact Us Lindsay Wilson HAST Tel: Fax:
Updates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationPaediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016
Paediatric ART: eligibility criteria and first line regimens (revised) Dave le Roux 13 August 2016 Outline Eligibility criteria for starting ART Evolving evidence for earlier ART W Cape, National, WHO
More informationtreatment VIRAL SUPPRESSION SUPPORT ART IS THE ONLY WAY TO CONTROL HIV TIPS FOR TAKING ART ADHERENCE Benefits of ART Start Know Your ARVs today ARVs
treatment Benefits of ART Know Your ARVs Start ARVs today SUPPORT VIRAL SUPPRESSION TIPS FOR TAKING ART ART IS THE ONLY WAY TO CONTROL HIV ADHERENCE HIV: BASIC FACTS HIV stands for the Human Immunodeficiency
More informationSUMMARY MEETING REPORT. Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service. Geneva, 7 8 May 2013
SUMMARY MEETING REPORT Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service Geneva, 7 8 May 2013 Department of HIV/AIDS HIV Technologies and Commodities May 2013 WHO/HIV/2013.6
More informationThe NEW ARV Guidelines FAQs
The NEW ARV Guidelines FAQs Dr Madeleine Muller MBChB (Pret).MRCGP(Lon).Dip Hiv Man IYDSA Clinical Advisor Acknowledgments IYDSA for materials and support NDOH for slides CDC our funder HIV Clinician Society
More informationA Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS OVERVIEW OF PRESENTATION Introduction : lessons learnt Availability ; implications of making paediatric formulations available Remaining challenges in
More informationClinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, User s Manual
Clinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, 2005 User s Manual Index 1. Overview 2. Scale-Up Assumptions 3. Procurement Assumptions 4. Clinical Assumptions 5.
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationList of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationConsiderations for the Introduction of TLD in National Programs: PEPFAR Guidance on Developing Clinical and Programmatic Recommendations
Considerations for the Introduction of TLD in National Programs: PEPFAR Guidance on Developing Clinical and Programmatic Recommendations December 2018 2 Table of Contents ACRONYMS... 3 INTRODUCTION...
More informationCan we make first line ART better?
Can we make first line ART better? Dr Angela Hartwig 8 th SA AIDS Conference, Durban Skills Building Session 15 June 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationAdvancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new
Advancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new H I V / A I D S D e p a r t m e n t WHO HQ Meg Doherty, MD, MPH, PhD Coordinator Treatment and Care November 5, 2012 1 Overview
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationFixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment
Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment Dr. David Pugatch Clinton Foundation Phnom Penh, Cambodia February, 2007 Lecture Goals To introduce and define fixed dose
More informationnevirapine, zidovudine and lamivudine
nevirapine, zidovudine and lamivudine a fixed dose ART combination for HIV treatment http://www.aidsmap.com/hatip nevirapine. zidovudine and lamivudine (non-fixed dose) 2 Information on starting treatment
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationMonographs on ARV and hepatitis medicines in The International Pharmacopoeia
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active
More informationADVANCED CLINICAL CARE JOB AIDES VERSION1- MARCH 2018
ADVANCED CLINICAL CARE JOB AIDES VERSION1- MARCH 2018 DISCLAIMER The Advanced Clinical Care (ACC), Job Aides was made possible by the support of the American People through the Centres for Disease Control
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationINITIATING ART IN CHILDREN: Follow the six steps
INITIATING ART IN CHILDREN: Follow the six steps STEP 1: DECIDE IF THE CHILD HAS CONFIRMED HIV INFECTION Child < 18 months: HIV infection is confirmed if the PCR is positive and the VL is more than 10,000
More informationANTIRETROVIRAL THERAPY IN NAMIBIA
ANTIRETROVIRAL THERAPY IN NAMIBIA SAHIVCS CONFERENCE CAPETOWN 25-28- NOVEMBER 2012 DR. F. MUGALA MUKUNGU M.MED (INT.MED) SPECIALIST PHYSICIAN KATUTURA STATE HOSPITAL WINDHOEK NAMIBIA Current status in
More informationWorld Bank Training Program on HIV/AIDS Drugs
World Bank Training Program on HIV/AIDS Drugs Training Module 3 Selection and Quantification based on the World Bank document Battling HIV/AIDS: A Decision Maker s Guide to the Procurement of Medicines
More informationUPDATE TRAINING ARV TREATMENT GUIDELINES TRAINERS CASE STUDIES & ANSWER GUIDE
UPDATE TRAINING ARV TREATMENT GUIDELINES TRAINERS CASE STUDIES & ANSWER GUIDE 3/13/2013 Contents Group Work Instructions... 2 PMTCT... 3 Case Study 1: Unbooked Pregnant Women... 3 Case Study 2: First ANC
More informationARV Market Report. The State of the Antiretroviral Drug Market in Low- and Middle-Income Countries. ISSUE 4, November 2013
ARV Market Report The State of the Antiretroviral Drug Market in Low- and Middle-Income Countries ISSUE 4, November 213 ARV Market Report Clinton Health Access Initiative 1 Table of Contents TABLE OF EXHIBITS...
More information2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall
2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationTRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES
POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment
More informationThe Western Cape Consolidated Guidelines for HIV Treatment: Prevention of Mother- to- Child Transmission of HIV (PMTCT), Children, Adolescents and
The Western Cape Consolidated Guidelines for HIV Treatment: Prevention of Mother- to- Child Transmission of HIV (PMTCT), Children, Adolescents and Adults. 2018 (Amended Version) The Western Cape Consolidated
More informationCan we make first line ART better?
Can we make first line ART better? Dr David Stead Treatment Optimization HIV Clinicians Society Workshop 25 November 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationZAMBIA DEX QUARTERLY REPORTS
ZAMBIA DEX QUARTERLY REPORTS Reporting Period: January June 2015: Global Fund Single Stream of Funding (SSF) HIV/AIDS Project Country Office: Annual Umbrella Authority: Project Specific Authority Substantive
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationCLAUDINE HENNESSEY & THEUNIS HURTER
HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationPatient s perceptions of switching from Atripla to Truvada and generic efavirenz
Patient s perceptions of switching from Atripla to Truvada and generic efavirenz Dr Hardeep Kang (ST4) Dr John Sweeney (Consultant) Background Atripla was approved as a fixed dose combination drug in 2006
More informationnevirapine, stavudine and lamivudine
nevirapine, stavudine and lamivudine Information on starting treatment with: nevirapine (NVP) + stavudine (d4t) + lamivudine (3TC) Nevirapine, stavudine and lamivudine (non-fixed dose) 2 Lead in dosing
More information1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016
To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical
More informationSESSION VI: Forecasting, estimating requirements for Procurement of HIV related supplies
ENSURING SECURE and RELIABLE SUPPLY and DISTRIBUTION SYSTEMS in DEVELOPING COUNTRIES, in the CONTEXT OF HIV/AIDS and PMTCT SESSION VI: Forecasting, estimating requirements for Procurement of HIV related
More informationGuidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017
Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017 Scottish Health Protection Network HIV Clinical Leads FINAL Approved for circulation 17 May 2017 Version No. 6.2 (04/05/17) Date
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationMODERN ART FOR AFRICA
MODERN ART FOR AFRICA March 2018 A guide for HIV treatment activists and communities in lowand middle-income countries ART today A pricing agreement was recently announced that will speed up access to
More informationQ&A on Second-Line HIV/AIDS Treatment
Q&A on Second-Line HIV/AIDS Treatment Q. What are second-line antiretrovirals? How are they different from first-line ARVs and why do they cost more? A. Over time, a patient s initial regimen of ARV medications
More informationFurther publications can be obtained from the HIV/AIDS Unit, Department of Communicable Diseases, World Health Organization, Regional Office for
Further publications can be obtained from the HIV/AIDS Unit, Department of Communicable Diseases, World Health Organization, Regional Office for South-East Asia, World Health House, Indraprastha Estate,
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationPersistent low level viraemia on third line ART
Persistent low level viraemia on third line ART Dr Richard Lessells XXVII International workshop on HIV drug resistance and treatment strategies October 2018 46-year old HIV-positive female HIV diagnosis
More informationSHOULD A TRIAL EVALUATING THE USE OF LOW DOSE STAVUDINE BE CONDUCTED?
SHOULD A TRIAL EVALUATING THE USE OF LOW DOSE STAVUDINE BE CONDUCTED? ETHICAL, CLINICAL AND COMMUNITY CONSIDERATIONS Eric Goemaere, MD, DTMH, PHD Senior HIV/TB program adviser MSF South Africa We loved
More informationThe Western Cape Consolidated Guidelines for HIV Treatment: Prevention of Mother- to- Child Transmission of HIV (PMTCT), Children, Adolescents and
The Western Cape Consolidated Guidelines for HIV Treatment: Prevention of Mother- to- Child Transmission of HIV (PMTCT), Children, Adolescents and Adults. 2015 (Amended Version) The Western Cape Consolidated
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationd4t-3tc-nvp stavudine lamivudine nevirapine Morning: d4t-3tc-nvp (Combined tablet) Evening: d4t and 3TC (2 separate tablets)
Now, you are on ART d4t-3tc-nvp stavudine lamivudine nevirapine Week 1-2 d4t-3tc-nvp (Combined tablet) d4t and 3TC (2 separate tablets) Week 3 and after Combined tablet Combined tablet Remember that: If
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationJames Nuttall Paediatric Infectious Diseases Unit Red Cross Children s Hospital
James Nuttall Paediatric Infectious Diseases Unit Red Cross Children s Hospital Paediatric HIV Infection Symposium, August 21, 2010, Red Cross Children s Hospital Overview of talk The 2010 paediatric guidelines
More informationWHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment
WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment Boniface Dongmo Nguimfack HIV/Technology and Commodities 1 AMDS
More informationClinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents
Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents Reference: NHS England F03X08 First published: Month Year Prepared by NHS England Specialised
More informationClinical guidelines for the management of HIV/AIDS in adults and adolescents 15 years. SAHIVCS - CME 13/06/15 DR.Henry Sunpath
Clinical guidelines for the management of HIV/AIDS in adults and adolescents 15 years SAHIVCS - CME 13/06/15 DR.Henry Sunpath 1 Introduction What is new? Goals and objectives Guiding principles HIV continuum
More informationREVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)
Expert peer review on application for addition of fixed dose combination formulations of antiretroviral medications in the EML (Adults) REVIEW No. 2 Abacavir + lamivudine (ABC+ 3TC) Tablet (dispersible):
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationUpdate on global guidelines. and emerging issues on perinatal HIV prevention. WHO 2013 Consolidated ARV Guidelines
WHO 2013 Consolidated ARV Guidelines Update on global guidelines H I V / A I D S DEPARTMENT and emerging issues on perinatal HIV prevention Children & HIV, St. Petersburg, Russia Sept 25-26, 2014 Dr. Nathan
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationAdolescents Living with HIV
Adolescents Living with HIV Gary Reubenson Polokwane 22 August 2015 Conflicts of Interest No relevant conflicts of interest to declare Acknowledgements Karl Technau Lee Fairlie Gill Sorour HIV Clinicians
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationCADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs
CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs Meg Doherty, Treatment and Care Coordinator WHO HQ Outline What s new in ARV Guidelines Drug optimisation
More informationUpdate on the IATT Paediatric Formulary. WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland
Update on the IATT Paediatric Formulary WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland Summary The Challenge Rationale for Paediatric ARV Formulary Optimization 2015 Revised
More informationDidactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching
Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University
More information25 October 2005 INTRODUCTION
Relative market share of different antiretroviral compounds in low and middle income countries in 2004 and 2005: an analysis of 2 public domain data bases Prepared by the AIDS Medicines and Diagnostics
More informationDifference of opinion? Michelle Moorhouse 24 Sep 2014
Difference of opinion? Michelle Moorhouse 24 Sep 2014 Meet NN 52 years, female Nurse in pre-art clinic Referred Feb 2012 by dermatologist History of severe reactions to ART Erythema and bullous eruptions
More informationTechnical Guidance Note for Global Fund HIV Proposals. TREATMENT - Antiretroviral Treatment-infants, children and adults
Technical Guidance Note for Global Fund HIV Proposals TREATMENT - Antiretroviral Treatment-infants, children and adults May 2010 This technical brief is designed to provide key technical information to
More informationSUMMARY BRIEF: SIX KEY QUESTIONS AND ANSWERS
INTERNAL BRIEFING AND QUESTIONS AND ANSWERS KIT ON THE LAUNCHES OF WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION, 2013 AND GLOBAL UPDATE ON HIV
More informationClinical Management Guidelines 2012
Central American Course Monitoring and Evaluation for HIV/AIDS Policy and Program Management 1 2 3 4 Module 1 Unit 1 Clinical Management Guidelines 2012 National TB, HIV/AIDS & other STIs Programme Ministry
More informationState of Industry Readiness for the New Demand Following the New Treatment Guidelines
JOINT MEDICINES PATENT POOL & WHO SATELLITE ON BRIDGING THE NEW TREATMENT GAP: WHAT WILL IT TAKE? State of Industry Readiness f the New Demand Following the New Treatment Guidelines Louis J. Riceberg,
More informationRegistration and Quality Assurance of ARVs and other Essential Medicines in Namibia
Registration and Quality Assurance of ARVs and other Essential Medicines in Namibia October 2014 September 2015 Registration and Quality Assurance of ARVs and other Essential Medicines in Namibia Nasser
More informationPaediatric HIV Resistance Referal Pathway. Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal
Paediatric HIV Resistance Referal Pathway Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal Third line Antiretroviral treatment options in HIV positive
More informationDEPARTMENT. Treatment Recommendations for. Pregnant and Breastfeeding Women: Critical Issues Consolidated ARV Guidelines. Dr.
2013 Consolidated ARV Guidelines H I V / A I D S Treatment Recommendations for DEPARTMENT Pregnant and Breastfeeding Women: Critical Issues Dr. Nathan Shaffer Objectives of Presentation obackground ooverview
More informationThe International Pharmacopoeia - Overview
The International Pharmacopoeia - Overview Caroline Mendy - Technical Officer Quality Assurance and Safety: Medicines World Health Organization 1 The International Pharmacopoeia Ph. Int. Scope WHO Consultative
More informationThe Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland
The Medicines Patent Pool: An Update June 2012 Geneva, Switzerland The Medicines Patent Pool Royalties Licensor Licensor Patents Generics versions of existing compounds Licensor Licensor Patents Patents
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationART rapid scale up: the implications for patient care and retention. Dr Francesca Conradie Southern African HIV Clinicians Society
ART rapid scale up: the implications for patient care and retention Dr Francesca Conradie Southern African HIV Clinicians Society Agenda Why do we need rapid scale up? Is there enough evidence for rapid
More informationUpdates on Paediatric HIV DCH 2018
Updates on Paediatric HIV DCH 2018 Dr James Nuttall Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital & University of Cape Town james.nuttall@uct.ac.za HIV
More informationTransaction Prices for Antiretroviral Medicines from 2010 to Global Price Reporting Mechanism
SUMMARY report AIDS medicines and diagnostics service Transaction Prices for Antiretroviral Medicines from 2010 to 2013 Global Price Reporting Mechanism December 2013 AIDS medicines and diagnostics service
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationRevised Anti- Retroviral Treatment Guideline Update For Frontline Clinical Health Professionals 3/13/2013
Revised Anti- Retroviral Treatment Guideline Update For Frontline Clinical Health Professionals 3/13/2013 The following document highlights the changes National department of Health ARV treatment guidelines
More informationPatients First! Gilles Van Cutsem, MSF
Patients First! Patients First! Gilles Van Cutsem, MSF Access Campaign: 1999-2010 Bearing Witness We are not certain that by speaking we will necessarily be able to save lives, but we know for certain
More informationTitle: What ARV regimen to start in children 3 years old? (TDF)
Title: What ARV regimen to start in children 3 years old? (TDF) Contents 1. PICO question... 1 2. Search strategy... 1 3. Flow diagram of screening process... 2 4. Evidence summaries... 2 5. Bibliography
More informationEmtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers
Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers About emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP
More informationUpdate on the Medicines Patent Pool
Update on the Medicines Patent Pool Sandeep Juneja November 06, 2012 How the Pool works* The Pool is an innovative licensing mechanism for HIV medicines Licensors Patents Feedback Market Impact Product
More informationThe Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
More informationInvitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationOccupational and Non- Occupational HIV Post-exposure Prophylaxis
Occupational and Non- Occupational HIV Post-exposure Prophylaxis Amy V. Kindrick, MD, MPH National Clinicians Post-Exposure Prophylaxis Hotline (PEPline) University of California, San Francisco San Francisco
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationIATT Optimal List of Paediatric ARV Formulations: Background and Update
IATT Optimal List of Paediatric ARV Formulations: Background and Update Nandita Sugandhi Clinton Health Access Initiative, USA PADO/IATT Update for ARV Manufacturers October 19, 2015 Overview Rationale
More informationUpdate on Option B+ Successes and Challenges. James McIntyre
Update on Option B+ Successes and Challenges James McIntyre Anova Health Institute & School of Public Health & Family Medicine, University of Cape Town Do not be fooled: People make simple things complex
More information